Scarica l'app Stockscreener
22.96
5.13%
1.12
Dopo l'orario di chiusura:
23.37
0.41
+1.79%
Precedente Chiudi:
$21.84
Aprire:
$21.95
Volume 24 ore:
1.58M
Relative Volume:
1.24
Capitalizzazione di mercato:
$2.88B
Reddito:
$247.00M
Utile/perdita netta:
$-353.00M
Rapporto P/E:
-6.9569
EPS:
-3.3003
Flusso di cassa netto:
$-484.00M
1 W Prestazione:
+8.25%
1M Prestazione:
-4.09%
6M Prestazione:
+71.73%
1 anno Prestazione:
+191.00%
Intervallo 1D:
$21.52
$23.45
Intervallo di 1 settimana:
$20.00
$23.45
Portata 52W:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
22.96 | 2.88B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
RCUS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences (NYSE:RCUS) Trading 5.4% Higher Following Analyst Upgrade - MarketBeat
RCUS: Wedbush Raises Price Target for Arcus Biosciences | RCUS S - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00 - MarketBeat
RCUS Technical Analysis & Stock Price Forecast - intellectia.ai
Gainers Report: Will Arcus Biosciences Inc stock benefit from M A2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
Behavioral Patterns of RCUS and Institutional Flows - Stock Traders Daily
Insider Trends: Is Arcus Biosciences Inc still a buy after recent gains2026 Retail Activity & Real-Time Volume Analysis Alerts - baoquankhu1.vn
RCUS Price History for Arcus Biosciences Stock - Barchart.com
Arcus Biosciences (RCUS) Vanguard shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Arcus Biosciences (NYSE:RCUS) Upgraded at Truist Financial - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcus Executives Offload Shares Amid Surge in Hiring—A "Pump and Dump" Warning Sign for RCUS - Bitget
Two new hires get Arcus stock awards priced at $21.41 a share - Stock Titan
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. Files Form 8-K with SEC for Common Stock Listed on NYSE (RCUS) - Minichart
Arcus Biosciences, Inc. Announces Resignation of Jennifer Jarrett as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Arcus Biosciences Announces COO Resignation and Transition Plan - TipRanks
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 - Investing.com Australia
Arcus Biosciences' Jennifer Jarrett to Resign as COO, Effective March 30, 2026 - TradingView
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 By Investing.com - Investing.com South Africa
Arcus Biosciences COO Jennifer Jarrett to resign March 30 - StreetInsider
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor - Stock Titan
Aug Setups: Can Arcus Biosciences Inc stock double in the next year2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS PE Ratio & Valuation, Is RCUS Overvalued - intellectia.ai
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences, Inc. (RCUS) Stock Price History & Data - Traders Union
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - MSN
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data - TradingView
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):